

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Rachael Ann ANCLIFF et al.

Serial No.: To be assigned

Art Unit:

Filing Date: Concurrently herewith

Examiner:

For: *Morpholinyl-urea Derivatives for use of the Treatment of Inflammatory Diseases*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appear in the Official Gazette of the United States Patent and Trademark Office, as ordered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.98(d).

- ☒ Copies of the references listed on the attached form PTO-1449 as item nos. 1, 4 and 15 are enclosed.
- ☐ Copies of the references were submitted in parent application Serial No. _____ (37 CFR 1.98(d)).
- ☒ A copy of the International Search Report which issued on International Application No. PCT/EP03/03335 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 as item nos. 1, 4 and 15. Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau of the World Intellectual Property Organization.

A. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).

OR

☐ The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).

B. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but **before** the mailing date of either:

- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,
- whichever occurs first.

☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

☐ Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).

10/509162

DT09 Rec'd PCT/PTO 27 SEP 2004

- C. ☐ The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- ☐ Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- ☐ Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- ☐ The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

☐ A duplicate copy of this paper is attached.

Respectfully Submitted,


James P. Rick
Attorney of Record
Registration No. 39,009

Date: September 24, 2004
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8022
Facsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				ATTORNEY DOCKET NO. PG4784USw		SERIAL NO. To be assigned	
				APPLICANT Rachael Ann ANCLIFF et al.		10/509162	
				FILING DATE Concurrently herewith			
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	5,389,635	02/14/1995	OLSON			
	2.	5,919,776	07/06/1999	HAGMANN et al.			
	3.	6,031,097	02/29/2000	HE et al.			
Continue on page _____							
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	4.	JP 04208267	07/29/1992	JP			
	5.	EP 0306440 *	03/08/1989	EPO			X
	6.	WO 95/32196 *	11/30/1995	WIPO			X
	7.	WO 96/02534	02/01/1996	WIPO			X (Abstract)
	8.	WO 96/39386 *	12/12/1996	WIPO			X
	9.	WO 97/47601 *	12/18/1997	WIPO			X (Abstract)
	10.	WO 98/56771 *	12/17/1998	WIPO			X
	11.	WO 99/06384 *	02/11/1999	WIPO			X
	12.	WO 99/21848 *	05/06/1999	WIPO			X
	13.	WO 00/18767 *	04/06/2000	WIPO			X
	14.	WO 02/26722 *	04/04/2002	WIPO			X
	15.	WO 02/26723	04/04/2002	WIPO			X
Continue on page _____							
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	16.	Dressman et al., "Solid phase synthesis of urea libraries using a diversifiable thiophenoxy carbonyl linker," <i>Tetrahedron Letters</i> 39(22):3631-3634 (May 1998).					
	17.	Makabe et al., "Synthesis of some nucleoside analogs of substituted 1,2,3-triazole," <i>Bull. Chem. Soc. Jap.</i> 45(8):2577-2579 (1972).					
	18.						
	19.						
	20.						
	21.						
	22.						
	23.						
	24.						
	25.						
Continue on page _____							
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							